Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018

  • Posted by: Biocon Biologics

Bengaluru, Karnataka, India, October 30, 2018

Biocon Ltd, Asia’s premier biopharmaceuticals company, has moved up in the Top 10 Global Biotech Employers ranking for 2018 and continues to be the only Company from Asia to feature on the prestigious U.S.-based Science magazine’s annual ‘Science Careers Top 20 Employers’ list, since its debut in 2012. Ranked at No. 7 amongst global pharma and biotech companies in 2018, Biocon’s position has moved up two ranks from No. 9 last year. Biocon has been recognized for these three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘makes changes needed’.

The ranking is a result of a global survey conducted by the Science magazine to determine which companies in the biotech and pharmaceutical industry have the best reputations as employers globally.

Kiran Mazumdar Shaw, CMD , Biocon said: “We are delighted to be ranked at No. 7 on Science magazine’s Top Global Pharma & Biotech Employers List for 2018. This is a recognition of Biocon’s high-end scientific talent who are aligned with the vision of a socially responsible organization that is making a difference to global healthcare through innovation and affordable access for patients. It encourages us to continue our journey of endurance with a focus on nurturing a culture of quality and compliance aimed at operational excellence. It is also a recognition of the grit, courage and commitment needed to emerge among the frontrunners in the global biosimilars race while operating in India’s risk-averse investment environment.”

The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the best employers in these industries, as well as their driving characteristics. This year more than 8,000 people participated, the most in the history of the survey; and these respondents were from North America (63%), Europe (24%), and Asia/Pacific Rim (9%); 93% of these were from biotechnology, biopharmaceutical, and pharmaceutical companies.

The overall driving characteristics of top employers as per survey respondents are ‘innovative leader in the industry’, ‘work culture values aligned’, ‘treats employees with respect’, ‘is socially responsible’, and ‘makes changes needed’. Some of the other leading global players are Regeneron, Novozymes, Merck KGaA, Novo Nordisk, Genentech, AbbVie etc.

Top 20 Employers for 2018:

The 20 companies with the best reputations as employers and the top three driving characteristics for each company, according to respondents in the 2018 survey undertaken for the Science/AAAS Custom Publishing Office. The companies without a 2017 rank did not receive enough mentions to qualify or did not receive a high enough ranking during the 2017 survey.

Survey responses were analysed by The Brighton Consulting Group, which used a mathematical process to assign a unique score to rate each company’s employer reputation. Each company received a ranking, for example, on the basis of whether it treats its employees with respect, whether its work-culture values align with employees’ personal values, and other factors.

About AAAS:
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science ( as well as Science Translational Medicine, Science Signaling, a digital, open-access journal, Science Advances, Science Immunology, and Science Robotics. AAAS was founded in 1848 and includes nearly 250 affiliated societies and academies of science, serving 10 million individuals. The non-profit AAAS ( is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, public engagement, and more.
Read More:

About Biocon:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully-integrated, innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and taken differentiated Small Molecules, Novel Biologics and a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh-Insulin and Insulin Glargine) from ‘Lab to Market’ in India, key emerging and developed markets. It has a large portfolio of biosimilars under clinical development with three of these approved in developed markets of US, EU, Japan and Australia. Its Novel pipeline includes promising assets like Insulin Tregopil, anti-CD6 antibody and a fusion protein for immuno-oncology. Some of its key brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). Follow-us on Twitter: @bioconlimited,

Author: Biocon Biologics